Drugs / TGD001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07459114 | May 2026 → May 2028 expected | autoimmune thrombocytopenia, thrombotic microangiopathy | TargED Biopharmaceuticals B.V. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGD001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07459114 ↗ |
| Route | Intravenous | “TGD001 IV bolus administration” NCT07459114 ↗ |